Moderately Hypofractionated Conformal Radiation Treatment of Thoracic Esophageal Carcinoma

  • Ma, Jin-Bo ;
  • Wei, Lin ;
  • Chen, Er-Cheng ;
  • Qin, Guang ;
  • Song, Yi-Peng ;
  • Chen, Xiang-Ming ;
  • Hao, Chuan-Guo
  • Published : 2012.08.31


Aims: To prospectively assess the efficacy and safety of moderately hypofractionated conformal radiotherapy in patients with thoracic esophageal cancer. Methods and Materials: From Sept. 2002 to Oct, 2005, 150 eligible patients with T2-4N0-1M0 stage thoracic esophageal squamous cell cancers were enrolled to receive either conventional fractionated radiation (CFR) or moderately hypofractionated radiation (MHR) with a three-dimensional conformal radiation technique. Of the total, 74 received moderately hypofractionated radiation with total dose of 54-60Gy/18-20fractions for 3.5-4 weeks in the MHR arm, and 76 received conventional radiation with total dose of 60Gy/30 fractions for 6 weeks in the CFR arm. Concurrent chemotherapy comprised of paclitaxel and cisplatin. Safety was evaluated, and local control and overall survival rates were calculated. Results: Statistically significant differences between the CFR versus MHR arms were observed in local/regional failure rate (47.3% v 27.0%, P=0.034) and the percentage of patients with persistent local disease (26.3% v 10.8%, P=0.012). But 3 and 5-year overall survival rates (43.2%, 38.8% v 38.2%, 28.0%, respectively) were not different between the two arms (P=0.268). There were no significant differences in the incidences of grade 3 or higher acute toxicities (66.3% v 50.0%) and late complications rates (27.0% v 22.4%) between the MHR and CFR arms. Conclusions: Moderately hypofractionated, three-dimensional radiation treatment could improve the local control rate of esophageal cancer and potentially increase patients' survival.


Chemoradiation;esophageal cancer;hypofractionated radiation


  1. Atsumi K, Shioyama Y, Nakamura K, et al (2010). Predictive factors of esophageal stenosis associated with tumor regression in radiation therapy for locally advanced esophageal cancer. J Radiat Res, 51, 9-14.
  2. Bao S, Wu Q, McLendon RE, et al (2006). Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature, 444, 756-60.
  3. Brunner T B, Rupp A, Melzner W, et al (2008). Esophageal cancer. A prospective phase II study of concomitant-boost external-beam chemoradiation with a top-up endoluminal boost. Strahlenther Onkol, 184, 15-22.
  4. Cooper JS, Guo MD, Herskovic A, et al (1999). Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA, 281, 1623-7.
  5. Gaspar LE, Winter K, Kocha WI, et al (2000). A phase I/II study of external beam radiation, brachytherapy, and concurrent chemotherapy for patients with localized carcinoma of the esophagus (Radiation Therapy Oncology Group Study 9207): final report. Cancer, 88, 988-95.<988::AID-CNCR7>3.0.CO;2-U
  6. Greene FL, Compton C, Fritz A, et al (2006). Esophagus., AJCC Cancer Staging Atlas. Springer Science+Business Media Inc, Chicago, pp. 77-88.
  7. Halperin EC, Perez CA, Brady LW, et al (2008). Biologic Basis of Radiation Therapy. In: McBride W.H. and Withers H.R. (eds.), Perez and Brady's principles and practice of radiation oncology. Lippincott Williams & Wilkins, Lippincott Williams & Wilkins, pp. 77-109.
  8. Hama Y, Uematsu M, Shioda A, et al (2002). Severe complications after hypofractionated high dose rate intracavitary brachytherapy following external beam irradiation for oesophageal carcinoma. Br J Radiol, 75, 238-42.
  9. Harney J, Goodchild K, Phillips H, et al (2003). A phase I/II study of CHARTWEL with concurrent chemotherapy in locally advanced, inoperable carcinoma of the oesophagus. Clin Oncol (R Coll Radiol), 15, 109-14.
  10. Hermann PC, Huber SL, Herrler T, et al (2007). Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell, 1, 313-23.
  11. Kassam Z, Wong RK, Ringash J, et al (2008). A phase I/II study to evaluate the toxicity and efficacy of accelerated fractionation radiotherapy for the palliation of dysphagia from carcinoma of the oesophagus. Clin Oncol (R Coll Radiol), 20, 53-60.
  12. Kawaguchi Y, Nishiyama K, Miyagi K, et al (2011). Patterns of failure associated with involved field radiotherapy in patients with clinical stage I thoracic esophageal cancer. Jpn J Clin Oncol, 41, 1007-12.
  13. Khurana R, Dimri K, Lal P, et al (2007). Factors influencing the development of ulcers and strictures in carcinoma of the esophagus treated with radiotherapy with or without concurrent chemotherapy. J Cancer Res Ther, 3, 2-7.
  14. Lee Y, Auh SL, Wang Y, et al (2009). Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood, 114, 589-95.
  15. Minsky BD, Pajak TF, Ginsberg RJ, et al (2002). INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: highdose versus standard-dose radiation therapy. J Clin Oncol, 20, 1167-74.
  16. Nguyen GH, Murph MM, Chang J Y (2011). Cancer Stem Cell Radioresistance and Enrichment: Where Frontline Radiation Therapy May Fail in Lung and Esophageal Cancers. Cancers (Basel), 3, 1232-52.
  17. Seung SK, Smith JW, 2nd, Ross HJ (2008). Selective dose escalation of chemoradiotherapy for locally advanced esophageal cancer. Dis Esophagus, 21, 589-95.
  18. Song YP, Ma JB, Hu LK, et al (2011). Phase I/II study of hypofractioned radiation with three-dimensional conformal radiotherapy for clinical T3-4N0-1M0 stage esophageal carcinoma. Technol Cancer Res Treat, 10, 25-30.
  19. Sykes A J, Burt P A, Slevin N J, et al (1998). Radical radiotherapy for carcinoma of the oesophagus: an effective alternative to surgery. Radiother Oncol, 48, 15-21.
  20. Trotti A, Colevas AD, Setser A, et al (2003). CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol, 13, 176-81.
  21. Vogelius IS, Westerly DC, Cannon GM, Bentzen SM (2010). Hypofractionation does not increase radiation pneumonitis risk with modern conformal radiation delivery techniques. Acta Oncol, 49, 1052-7.
  22. Vuong T, Szego P, David M, et al (2005). The safety and usefulness of high-dose-rate endoluminal brachytherapy as a boost in the treatment of patients with esophageal cancer with external beam radiation with or without chemotherapy. Int J Radiat Oncol Biol Phys, 63, 758-64.
  23. Zhao KL, Ma JB, Liu G, et al (2010). Three-dimensional conformal radiation therapy for esophageal squamous cell carcinoma: is elective nodal irradiation necessary? Int J Radiat Oncol Biol Phys, 76, 446-51.

Cited by

  1. High-dose radiation therapy alone by moderate hypofractionation for patients with thoracic esophageal squamous cell carcinoma vol.95, pp.33, 2016,